A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 274 participants.
Also called NCT06323161
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 274 participants
- Sponsor
- Registry
-
NCT06323161
-
- Other papers using this trial's data
- Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, China, Japan, Serbia, Slovakia, South Africa
- Registry status
- Completed
Technical summary
Registry record NCT06323161. Randomized; quadruple masking; primary purpose treatment. Start 2024-03-26 (actual); primary completion 2025-09-09 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin
- Acronym
- REIMAGINE 3
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Cagrilintide
- Intervention (Drug)
- Semaglutide
- Intervention (Drug)
- Placebo
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct06323161- Content hash
2ab7894adfb0ede5afb10e1b316c5553e0e103a5a0c198eccdf8c77ffa329f51